Managed Care Insights on Optimizing Coordination of Care for Effective Management of CLL

Program Description

Though use of targeted oral BTK and BCL-2 inhibitors has improved quality of life for patients with chronic lymphocytic leukemia (CLL), challenges remain, namely indefinite length of treatment, that has led to adverse effects and resistance that increase discontinuation rates. This activity will explore evidence for double- and triple-therapy combinations to achieve fixed-duration treatment for patients with CLL receiving BTK and BCL-2 inhibitors. Pharmacists must be involved in approaches that provide efficient, deeper responses, especially in high-risk patients, while minimizing resistance and toxicities. Guideline-recommended strategies for pharmacists to intervene in the management of adverse effects of treatment for patients on BTK inhibitors will be reviewed. One of the biggest challenges in the CLL treatment landscape is financial toxicity, and managed care pharmacists must be familiar with evidence to evaluate fixed-duration treatment regimens utilizing combination strategies with the potential to reduce resources for patients and the healthcare system.

Target audience: Oncology and managed care pharmacists

Type of activity: Application
Release date: July 7, 2022
Expiration date: July 7, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate challenges in current treatment approaches in chronic lymphocytic leukemia (CLL) and emerging data on combination therapies and fixed-duration strategies
• Differentiate the safety profiles for BTK inhibitors as well as monitoring and management strategies to mitigate adverse effects
• Analyze the cost drivers associated with the management of CLL and the value of evolving treatment approaches in lowering cost of care and healthcare utilization

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-329-H01-P. The activity is available for CE credit through July 7, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Kelly Valla, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Speaker’s Bureau: BeiGene

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms